Pipecolisporin, a novel cyclic peptide with interesting antiparasitic properties
March 16, 2021: A new article published by researchers at MEDINA reports the discovery a new cyclic peptide with interesting antiparasitic properties. This new natural product has been isolated from cultures of a wheat endophytic fungus, Nigrospora oryzae. It was...
MEDINA in collaboration with UGR researchers describes a panel of potential biomarkers of malignant melanoma
Melanoma is a type of skin cancer that originates when melanocytes (the cells that give skin its tan or brown color) begin to grow out of control. Melanoma is much less common than other types of skin cancers. But melanoma is more dangerous because it is much more...
BEST PhD THESIS IN TAXONOMY, PHYLOGENY AND DIVERSITY AWARD granted by the GROUP OF TAXONOMY, PHILOGENY AND MICROBIAN DIVERSITY of the SPANISH SOCIETY OF MICROBIOLOGY
Granada, Spain October 26th 2020 Dr. Víctor González-Menéndez has been awarded the best DOCTORAL THESIS PRIZE FOR RESEARCH IN TAXONOMY, PHILOGENY AND DIVERSITY of the specialty in the years 2018 and 2019. This award is granted by the SPECIALIZED GROUP IN TAXONOMY,...
RADIOPROLIQ: research on liquid biopsy in prostate cancer.
November 12, 2020 Fundación MEDINA collaborates with its metabolomics platform in the DE R&D project on liquid biopsy in prostate cancer, led by the Recoletas Campo Grande Hospital, in alliance with IBSAL (Biomedical Research Institute of Salamanca) and Atrys...
Fundación MEDINA, DNDi and Institut Pasteur Korea announce new funding from “la Caixa” Health Research for research partnership to discover new natural products against leishmaniasis and Chagas disease
Granada, Spain September 28th 2020 Fundación MEDINA, DNDi and Institut Pasteur Korea announce new funding from “la Caixa” Health Research for research partnership to discover new natural products against leishmaniasis and Chagas disease Fundación MEDINA, the Drugs for...
MEDINA, Almirall and UC3M to research new treatments for rare genetic diseases
Granada: 28 May 2020 MEDINA, Almirall and UC3M to research new treatments for rare genetic diseases. Fundación MEDINA, Almirall, S.A. (ALM) and the University Carlos III Madrid (UC3M) have launched a project to find new treatments for recessive dystrophic...
MEDINA joins the global COVID-19 research effort looking for new therapeutics and diagnostic solutions for SARS-CoV-2.
MEDINA is a drug discovery organization and a partner site of the European research infrastructure EU-OPENSCREEN (www.eu-openscreen.eu). Leveraging our drug discovery expertise, the potential of our natural product libraries and the high throughput screening and...
Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics
New article by Fundacion MEDINA in collaboration with the Department of Oncology at the Ludwig Institute for Cancer Research of the University of Lausanne, the Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM) of the...
First evidence of anticancer and antimicrobial activity in Mediterranean mesopelagic species.
New article by Fundacion MEDINA in collaboration with the Marine Biotechnology Department at the Stazione Zoologica Anton Dohrn, Naples, and the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (ChiBioFarAm) of the University of Messina:...
BSP meeting Trypanosomiasis & Leishmaniasis Symposium: Novel Advances in Basic and Applied Research. March 8 – 11, Granada- Spain.
Dr. Freddie Annang, a specialist in drug discovery against parasitic diseases from Fundación MEDINA, attended the BSP meeting entitled “Trypanosomiasis & Leishmaniasis Symposium: Novel Advances in Basic and Applied Research” which took place in Granada from the...